Clinical trial · Observational
Fertility and Polycystic Ovary Syndrome
Description of Fertility and Pregnancies in Patients With Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and affects approximately 10% of women worldwide. The diagnosis is based on the Rotterdam criteria established in 2003 and updated in the latest recommendations from the European Society of Human Reproduction (ESHRE) in 2023. The diagnosis of PCOS is based on the presence of 2 of the following 3 criteria: 1. Oligo-anovulation 2. Clinical and/or biological hyperandrogenism 3. Polycystic ovary morphology (PCOM) on imaging It is also the leading cause of anovulatory infertility, with a 15-fold increased risk of infertility. It is therefore a major cause of anovulatory infertility, but its pathophysiological mechanisms remain complex and multifactorial, involving interactions between genetic, metabolic, hormonal, and environmental factors. Prior to embarking on a fertility treatment plan, it is essential to better understand how these various factors influence ovarian function and reproductive capacity in patients with PCOS. Identifying and characterizing factors associated with fertility-such as hormonal profiles, insulin sensitivity, and metabolic markers-could help better predict future fertility and optimize personalized care and fertility outcomes. The aim of this study is therefore to identify modifiable factors influencing the fertility of PCOS patients phenotyped at La Pitié-Salpêtrière hospital.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome (PCOS) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- PCOS patients
- description
- PCOS patients aged between 18 and 45 years
- interventionNames
- Other: Questionnaires
- label
- Control
- description
- Control (PCOS free)
- interventionNames
- Other: Questionnaires
Primary outcomes (1)
- measure
- Description of the mode of conception
- timeFrame
- Through study completion, an average of 1 year
- description
- Description of the mode of conception: spontaneous or induced; if induced, by which ART technique or following which treatment to improve PCOS symptoms (inositol, GLP-1 analog, metformin, lifestyle and dietary changes, etc.). These informations will be colected from medical records and frome the specific questionnaire.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria- PCOS group: * Aged between 18 and 45 years old * Female with a diagnosis of PCOS according to ESHRE criteria * Previouslu enrolled in METABOPK research Inclusion Criteria- Control group * Aged between 18 and 45 years old * Female with normal metabolic and hormonal profiles * Previouslu enrolled in METABOPK research Exclusion Criteria: * A prior diagnosis of type 1 or type 2 diabetes * A diagnosis of non-classical adrenal block * Use of hormonal therapy, oral antidiabetic medication, lipid-lowering medication, antihypertensive medication, corticosteroids, or spironolactone * Menopause or current pregnancy * Lack of data on BMI, insulin levels, and fasting blood glucose * Patients who do not speak French * Patients under legal guardianship, conservatorship, or curatorship
References
Publications (0)
Data not yet available